Encision Inc. Announces Fiscal 2026 Fourth Quarter and Full Year Results
Rhea-AI Summary
Encision (PK:ECIA) reported fiscal 2026 Q4 and full-year results for the period ending March 31, 2026. Q4 net sales were $1.241M, down 12.2% sequentially; Q4 gross margin rose to 47.7% from 38.4%. Year sales fell to $5.784M from $6.555M in 2025.
The company cut operating expenses, improved quarterly operating income versus prior quarter, and says restructuring completed by end-February eliminated near-term going-concern risk.
Positive
- Net sales down 12.2% sequentially but shows cost control
- Gross margin improved +9.3 percentage points QoQ to 47.7%
- Operating expenses reduced 22.6% QoQ
- Operating income improved 79.9% versus prior quarter
Negative
- Full-year net sales declined 11.7% YoY to $5.784M
- Full-year net loss widened to $719k from $220k a year earlier
- Operating margin worsened to -11.0% for fiscal 2026 from -2.6% in 2025
News Market Reaction – ECIA
In the Apr 13 session, ECIA gained 18.18%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, CO / ACCESS Newswire / April 13, 2026 / Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today reported its financial results for its 2026 fiscal fourth quarter and year end.
Encision's CEO Robert Fries commented, "The Company's sales were down
"By the end of February, we completed our restructuring and substantially reduced targeted operating expenses. As a result, we were profitable in March on an operating income basis and we expect the next quarter to be profitable, representing a turnaround from the losses of previous quarters."
After a review of the cash flow forecast for the next twelve months, there are no going-concern considerations.
Encision designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.
Encision Inc.
Condensed Statements of Operations
(unaudited)
Quarters ended | Variance versus prior quarter | |||||||||||||||
(in $ thousands) | March 31, 2026 | Dec. 31, 2025 | ($) | (%) | ||||||||||||
Net sales | 1,241 | 1,413 | -172 | -12.2 | % | |||||||||||
Cost of goods sold | 649 | 870 | -221 | -25.4 | % | |||||||||||
Gross profit | 592 | 543 | 49 | 9.0 | % | |||||||||||
Gross profit margin % | 47.7 | % | 38.4 | % | +9.3 | % | ||||||||||
Operating expenses | 652 | 842 | -190 | -22.6 | % | |||||||||||
Operating income | (60 | ) | (299 | ) | 239 | 79.9 | % | |||||||||
Operating margin % | -4.8 | % | -21.2 | % | +16.4 | % | ||||||||||
Interest and other expense, net | (36 | ) | (15 | ) | -21 | |||||||||||
Net loss | (96 | ) | (314 | ) | 218 | 69.4 | % | |||||||||
Years ended | ||||||||
(in $ thousands) | Mar. 31, 2026 | Mar. 31, 2025 | ||||||
Net sales | 5,784 | 6,555 | ||||||
Cost of goods sold | 3,073 | 3,044 | ||||||
Gross profit | 2,711 | 3,511 | ||||||
Gross profit margin % | 46.9 | % | 53.6 | % | ||||
Operating expenses | 3,348 | 3,683 | ||||||
Operating income | (637 | ) | (172 | ) | ||||
Operating margin % | -11.0 | % | -2.6 | % | ||||
Interest and other expense, net | (82 | ) | (48 | ) | ||||
Net loss | (719 | ) | (220 | ) | ||||
Contact:
Mala Ray
mray@encision.com
303-339-6901
SOURCE: Encision, Inc.
View the original press release on ACCESS Newswire